TAK-733 化学構造
分子量: 504.23



Quality Control & MSDS


  • Compare MEK Inhibitors
  • 研究分野
  • Combination Therapy
  • TAK-733のメカニズム



製品説明 TAK-733は、強力な、選択的な、ATP-非競争的MEKアロステリック部位阻害剤で、IC50 が 3.2nMです。
ターゲット MEK1
IC50 3.2 nM [1]
In vitro試験 TAK-733 is highly potent and selective MEK allosteric site inhibitor with IC50 of 3.2 nM. TAK-733 shows potent enzymatic and cell activity with an EC50 of 1.9 nM against ERK phosphorylation in cells. [1]
In vivo試験 TAK-733 demonstrates broad antitumor activity in mouse xenograft models of human cancer including models of melanoma, colorectal, NSCLC, pancreatic and breast cancer. TAK-733 is well tolerated with pharmacokinetics and pharmacodynamics that support once-daily oral dosing in humans. [1] TAK-733 shows maximally efficacious doses at once daily orally doses of 10 mg/kg. [2]
臨床試験 A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.

プロトコル (参考用のみ)

動物実験: [2]

動物モデル Human solid tumor xenograft models including NSCLC (NCI H23 [KRAS and LKB1 mutations]), CRC (SW620 [KRAS, APC, p53 mutations]) Pancreatic cancer (Panc 1 and Capan 1 [KRAS mutations] and BxPC-3 [No MAPK mutations]) models in immunocompromised mice.
製剤 Saline
投薬量 10 mg/kg
投与方法 Orally administrated once daily for 21 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download TAK-733 SDF
分子量 504.23


CAS No. 1035555-63-5
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 101 mg/mL (200.3 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione

カスタマーフィードバック (3)

Click to enlarge
Source Dr.Wang from Southern Medical Hospital . TAK-733 purchased from Selleck
Method Western blot
Cell Lines A549 cells
Concentrations 0-10 uM
Incubation Time 2 h
Results Effect of MEK inhibitor TAK-733 in A549 cells. A549 cells were incubated with increasing concentrations of TAK-733 for 2 h. The cell lysates were harvested and phosphorylation of indicated proteins was determined by Western blotting.

Click to enlarge
Source Jonas Nilsson, PhD from University of Gothenburg. TAK-733 purchased from Selleck
Method Western blot, cell apoptosis assays
Cell Lines Mouse carcinoma cells
Concentrations 1-1000 nM
Incubation Time 16/40 h
Results (A) whereas apoptosis was induced at 40h. (B) Biological effects of the compounds correlated with effects on phosphorylation of the MEK target ERK. (C) IC50 on S-phase and ERK-posphorylation: TAK-733=1-10 nM, GSK1120212=<1 nM.

Click to enlarge
Source Dr. Zhang of Tianjin Medical University. TAK-733 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations 0-10 μM
Incubation Time 3 h
Results Reduction of ERK1/2 phosphorylation in T47D cells treated with TAK-733 was observed.

文献中の引用 (2)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related MEK 阻害剤

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212)は、非常に特定で有力なMEK1MEK2 阻害剤で、IC50 がそれぞれ 0.92 nM と 1.8 nMです。

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901は選択的です、そして、非ATP競争的有糸分裂促進物質はMEK活動のinhibitonのためにプロテインキナーゼ・キナーゼ(MEKまたはMAPKK)MEK阻害剤を起動させました。IC50 が 0.33 nMになる。

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) は有効的にMEK1を抑制して、IC50 が14 nMになる.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH は化学的に合成されて非常に選択的な阻害剤で、MEK1 とMEK2 に作用すると、 IC50 がそれぞれ0.07 μM と 0.06 μMになる。

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059は、非競争的MEK</bです> 阻害剤で、IC50 が2 μMです.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • PD184352 (CI-1040)

    PD184352 (CI-1040)は、ATP非競争MEK1/2阻害剤で、IC50 が 17 nMです。

    Features:First MEK inhibitor to begin clinical development.


Tags: TAK-733を買う | TAK-733供給者 | TAK-733を購入する | TAK-733費用 | TAK-733生産者 | オーダーTAK-733 | TAK-733代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description